SGLT2 Inhibitors and Mechanisms of Arterial Hypertension

dc.contributor.author	Raimzhanov A.A
dc.contributor.author	Mangasaryan A.A.
dc.date.accessioned	2026-01-01T10:18:02Z
dc.date.issued	2023-03-08
dc.description.abstract	The article provides information about the use of SGLT2 inhibitors in hypertensive crises, mechanisms of action as an antihypertensive drug and the normalization of endothelial function. Other generation of these drugs are also compared with empagliflazin. Studies have been conducted with placebo drugs, and information is given on the effect of drugs on reducing daily and night blood pressure.
dc.format	application/pdf
dc.identifier.uri	https://zienjournals.com/index.php/tjms/article/view/3496
dc.identifier.uri	10.62480/tjms.2023.vol18.pp13-16
dc.identifier.uri	https://asianeducationindex.com/handle/123456789/59562
dc.language.iso	eng
dc.publisher	Zien Journals
dc.relation	https://zienjournals.com/index.php/tjms/article/view/3496/2902
dc.rights	https://creativecommons.org/licenses/by-nc/4.0
dc.source	Texas Journal of Medical Science; Vol. 18 (2023): TJMS; 13-16
dc.source	2770-2936
dc.subject	diabetes
dc.subject	hypertension
dc.subject	glucose
dc.subject	weight loss
dc.title	SGLT2 Inhibitors and Mechanisms of Arterial Hypertension
dc.type	info:eu-repo/semantics/article
dc.type	info:eu-repo/semantics/publishedVersion
dc.type	Peer-reviewed Article

item.page.files

pagination.showing.labelpagination.showing.detail

item.page.filesection.name: aa_2023_sglt2_inhibitors_and_mechanisms_of_arter.pdf
item.page.filesection.size: 166.21 KB
item.page.filesection.format: Adobe Portable Document Format